Brii said it agreed to purchase the assets from VBI Vaccines Inc. and its creditors for $18 million. The deal gives Brii full access to the remaining IP, patents and materials related to BRII-179, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback